Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.
Cowen and Leerink rated Quanterix at Outperform while JP Morgan initiated coverage with an Overweight rating — the banks managed the company's $74 million IPO.
The investment bank previously had a Neutral rating for the company, and it lowered the price target on Genomic Health's stock to $25 from $28.
The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.
The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.
Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.
The chemistry will be single-molecule, based on hybridization, and will not require amplification, enzymes, or library prep, the firm said.
Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.
Executives from the sequencing tech firms provided attendees with an update on recently launched products and platforms, and future technology developments.
Executives from 23andMe, Myriad Genetics, Genomic Health, and Alere provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.
Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.
The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.
Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.
In Nature this week: ash dieback disease fungal genome, and more.